These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 27491607)
1. The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. Povsic TJ; Henry TD; Traverse JH; Fortuin FD; Schaer GL; Kereiakes DJ; Schatz RA; Zeiher AM; White CJ; Stewart DJ; Jolicoeur EM; Bass T; Henderson DA; Dignacco P; Gu Z; Al-Khalidi HR; Junge C; Nada A; Hunt AS; Losordo DW; JACC Cardiovasc Interv; 2016 Aug; 9(15):1576-85. PubMed ID: 27491607 [TBL] [Abstract][Full Text] [Related]
2. A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Povsic TJ; Junge C; Nada A; Schatz RA; Harrington RA; Davidson CJ; Fortuin FD; Kereiakes DJ; Mendelsohn FO; Sherman W; Schaer GL; White CJ; Stewart D; Story K; Losordo DW; Henry TD Am Heart J; 2013 Jun; 165(6):854-861.e2. PubMed ID: 23708155 [TBL] [Abstract][Full Text] [Related]
3. Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Henry TD; Losordo DW; Traverse JH; Schatz RA; Jolicoeur EM; Schaer GL; Clare R; Chiswell K; White CJ; Fortuin FD; Kereiakes DJ; Zeiher AM; Sherman W; Hunt AS; Povsic TJ Eur Heart J; 2018 Jun; 39(23):2208-2216. PubMed ID: 29315376 [TBL] [Abstract][Full Text] [Related]